Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

BKM120 in Cancers With PIK3CA Activating Mutations

This study has been terminated.
(The study has been closed due to lack of accrual)
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jeffrey Engelman, Massachusetts General Hospital Identifier:
First received: December 27, 2011
Last updated: January 24, 2013
Last verified: January 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)